Vironova AB – Product Pipeline Review – 2012
SUMMARY
Global Market Direct’s pharmaceuticals report, “Vironova AB Product Pipeline Review - 2012” provides data on the Vironova AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vironova AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Vironova AB and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
SUMMARY
Global Market Direct’s pharmaceuticals report, “Vironova AB Product Pipeline Review - 2012” provides data on the Vironova AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vironova AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Vironova AB and industry-specific third party sources, put together by Global Markets Direct’s team.
SCOPE
- Vironova AB - Brief Vironova AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vironova AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vironova AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vironova AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Vironova AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vironova AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vironova AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vironova AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vironova AB and identify potential opportunities in those areas.
Vironova AB Snapshot
Vironova AB Overview
Key Information
Key Facts
Vironova AB – Research and Development Overview
Key Therapeutic Areas
Vironova AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vironova AB – Pipeline Products Glance
Vironova AB – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vironova AB – Drug Profiles
Drug for HIV-1
Product Description
Mechanism of Action
R&D Progress
Drug For Influenza A
Product Description
Mechanism of Action
R&D Progress
VN-180
Product Description
Mechanism of Action
R&D Progress
Vironova AB – Recent Pipeline Updates
Vironova AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Vironova AB, Deals Summary
Vironova AB, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Vironova Secures $15 Million In Venture Financing
Licensing Agreements
Vironova Enters Into Licensing Agreement With University of Maryland, Baltimore County
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Vironova AB, Key Information
Vironova AB, Key Facts
Vironova AB – Pipeline by Indication, 2012
Vironova AB – Pipeline by Stage of Development, 2012
Vironova AB – Monotherapy Products in Pipeline, 2012
Vironova AB – Pre-Clinical, 2012
Vironova AB – Discovery, 2012
Vironova AB – Recent Pipeline Updates, 2012
Vironova AB, Subsidiaries
Vironova AB, Deals Summary
Vironova Secures $15 Million In Venture Financing
Vironova Enters Into Licensing Agreement With University of Maryland, Baltimore County
List of Figures
Vironova AB – Pipeline by Indication, 2012
Vironova AB – Pipeline by Stage of Development, 2012
Vironova AB – Monotherapy Products in Pipeline, 2012
Vironova AB Overview
Key Information
Key Facts
Vironova AB – Research and Development Overview
Key Therapeutic Areas
Vironova AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vironova AB – Pipeline Products Glance
Vironova AB – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vironova AB – Drug Profiles
Drug for HIV-1
Product Description
Mechanism of Action
R&D Progress
Drug For Influenza A
Product Description
Mechanism of Action
R&D Progress
VN-180
Product Description
Mechanism of Action
R&D Progress
Vironova AB – Recent Pipeline Updates
Vironova AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Vironova AB, Deals Summary
Vironova AB, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Vironova Secures $15 Million In Venture Financing
Licensing Agreements
Vironova Enters Into Licensing Agreement With University of Maryland, Baltimore County
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Vironova AB, Key Information
Vironova AB, Key Facts
Vironova AB – Pipeline by Indication, 2012
Vironova AB – Pipeline by Stage of Development, 2012
Vironova AB – Monotherapy Products in Pipeline, 2012
Vironova AB – Pre-Clinical, 2012
Vironova AB – Discovery, 2012
Vironova AB – Recent Pipeline Updates, 2012
Vironova AB, Subsidiaries
Vironova AB, Deals Summary
Vironova Secures $15 Million In Venture Financing
Vironova Enters Into Licensing Agreement With University of Maryland, Baltimore County
List of Figures
Vironova AB – Pipeline by Indication, 2012
Vironova AB – Pipeline by Stage of Development, 2012
Vironova AB – Monotherapy Products in Pipeline, 2012
